Press Releases

Cystic Fibrosis Foundation Employs nSpire Health's IPL in Largest Multicenter Infant Lung Function Trial to Date

Longmont, Colorado, USA - May 2009 - nSpire Health’s Infant Pulmonary Laboratory has been chosen by the principal investigators for a large multicenter trial funded by the Cystic Fibrosis Foundation and the NIH for centralized gathering of data from seventeen (17) sites.

This study, involving preeminent pediatric research institutions in the US and Canada, will utilize nSpire Health’s Infant Pulmonary Laboratory (IPL). The IPL, considered the standard in raised volume infant pulmonary function testing, remains the world’s only device utilizing the patented raised volume technique.

“This is a large project in terms of numbers of study subjects in the infant lung function testing world. nSpire Health’s involvement guarantees foundation investigators that the highest quality lung function results are collected and coordinated throughout the study,” said Dave Filbrun, Product Manager for the IPL. “We are excited to work with this group involving so many premier pediatric institutions on a trial with such positive potential clinical significance.”

About nSpire Health
nSpire Health develops and manufactures respiratory care products and provides related services. The company is focused on cardiopulmonary diagnostics, respiratory core lab services, and disease management solutions designed to improve health care productivity while increasing the overall quality of care. nSpire Health is the exclusive provider of PiKo® home lung health monitors, Pocket™ asthma care, KoKo® spirometers, ZAN® measuring instruments, and HDpft™, the most accurate and precise pulmonary function testing systems worldwide.

For further information contact us at: kborgen@nspirehealth.com or visit us at www.nspirehealth.com/IPL

USA: 1.800.574.7374, + 1.303.666.5555
United Kingdom: +44 (0) 1992 526300
Germany: +49 (0) 9736 8181 0

About Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is a nonprofit donor-supported organization, founded in 1955, to assure the development of the means to cure and control cystic fibrosis and to improve the quality of life for those with the disease.  A leading organization in the United States devoted to cystic fibrosis, the Foundation funds and accredits more than 115 CF care centers, 95 adult care programs and 50 affiliate programs, and has 80 chapters and branch offices nationwide. 90 percent of every dollar of revenue raised by the Cystic Fibrosis Foundation is available to fund cystic fibrosis research, care and education programs.

For further information visit http://www.cff.org/